Business Wire

Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using AI in Anticancer and Regenerative Medicine

Share

Oncocross, a Seoul-based AI drug discovery and development biotech, announced on May 22nd that it has signed a joint research agreement with JW Pharmaceutical to develop new drugs based on the AI platform.

Under this contract, the two companies will join research efforts to identify and verify development possibilities for new indications for the 'first-in-class' drug pipeline that JW Pharmaceutical is developing in the area of anticancer and regenerative medicine.

For this purpose, Oncocross’s proprietary AI platform RAPTOR AITM will be utilized. RAPTOR AITM is an AI drug development platform that screens the optimal or additional indications for drug candidates or existing drugs. The platform provides AI capabilities necessary for pharmaceutical companies' new drug development, resulting in higher accuracy, reduced cost, and shorter development time compared to traditional methods.

Previously, the two companies signed a joint research agreement to identify new indications for drug candidates in 2022. Through this joint research, JW Pharmaceutical has secured positive data on expanding an orphan disease indication for the new drug candidate and is establishing a follow-up development plan.

Having previously verified the RAPTOR AITM technology, JW Pharmaceutical once again expects to reduce the time required for new indication screening and increase the probability of success in clinical studies for the 'first-in-class' drug pipelines.

JW Pharmaceutical said, “The level of innovation we are focusing on requires high R&D capabilities and substantial costs and time to discover new drug candidates and indications,” adding, “We will continue to pursue diverse partnerships with innovative local and global biotech companies that possess new technologies such as Oncocross.”

Dr. Yirang Kim, CEO of Oncocross commented, "This follow-on collaboration is significant in the sense that the utility and commercial value of RAPTOR AITM has been recognized in the market.” He further added, “We will continue to do our best to set examples of collaboration between large pharmaceutical companies and biotech in the AI drug development field.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Oncocross Co., Ltd.
Daniel Kim
+82-2-867-9967
daniel.kim@oncocross.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DentalMonitoring Sets New Standard in Orthodontic Remote Monitoring With EU-MDR Certification14.6.2024 19:33:00 CEST | Press release

DentalMonitoring is proud to announce that the DentalMonitoring Software is now certified under the European Union Medical Device Regulation 2017/745 (EU MDR) and fulfills the requirements for CE marking as a class IIa medical device. European Medical Device Regulation 2017/745 (EU MDR) replaces the previous Medical Device Directive 93/42/EEC (MDD). EU MDR sets more rigorous requirements for clinical evaluation, risk management, post-market surveillance, and data collection on medical devices.(1) This landmark achievement underscores DentalMonitoring's commitment to advancing dental care through cutting-edge technology and rigorous regulatory compliance. Achieving this certification four years ahead of the deadline demonstrates DentalMonitoring's commitment to positioning itself as an innovative, serious, efficient, and safe player in the medical field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614842101/en/ DentalMo

Argonne and a Moroccan University Sign Agreement to Advance Green Energy Tech and Computing14.6.2024 15:24:00 CEST | Press release

The U.S. Department of Energy’s (DOE) Argonne National Laboratory and University Mohammed VI Polytechnic (UM6P) have signed a memorandum of understanding (MOU) to collaborate on key areas of mutual interest related to green energy technology and the nexus of water and energy. In a ceremony held at UM6P’s campus in Benguerir, the MOU was signed by Argonne Laboratory Director Paul Kearns and UM6P President Hicham El Habti. “We are excited to see what discoveries and innovations will result from our ongoing partnership,” said Kearns. ​“By working together, we’ll open new scientific frontiers for both our countries’ futures.” “Today marks a significant milestone in our journey towards sustainable innovation. The signing of this Memorandum of Understanding with Argonne National Laboratory underscores our commitment to advancing research and development in renewable energy, energy grids, and water management. Together, we aim to leverage our collective expertise to create transformative solu

MultiBank Group Recognized as Top BaFin-Regulated Forex Broker14.6.2024 14:33:00 CEST | Press release

MultiBank Group is thrilled to announce its recognition as a top BaFin-regulated forex broker by FXEmpire, a leading financial markets authority. This prestigious accolade highlights MultiBank Group's unwavering commitment to excellence, security, and innovation in the forex trading industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614306878/en/ Top BaFin regulated forex broker 2024 (Graphic: Business Wire) About BaFin: Regulating German Financial Markets BaFin, Germany's Federal Financial Supervisory Authority, oversees the country's banking, securities, and insurance sectors. It ensures fair and transparent operations in the forex and CFD markets by enforcing rigorous standards. Selection Methodology FXEmpire's methodology for selecting the best BaFin-regulated brokers includes: Regulation Verification: Ensuring each broker is BaFin-regulated, providing traders with high-level protection. Cost Efficiency: Brokers

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)14.6.2024 14:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license global rights to develop and commercialize olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia. Despite the impact TKIs have had in the treatment of patients with CML, there remains significant unmet need for patients whose disease is resistant or refractory to these therapies or who develop hard-to-treat mutations following these treatments. “Takeda has a long history of driving important treatment advances for patients, particularly those with hematological cancers facing treatment gaps,” said Teresa Bitetti, president of the Globa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye